Recently, three important studies have demonstrated the clinical prognostic relevance of Tks5 expression in glial-derived brain tumors [14], lung adenocarcinomas [15] and prostate cancer [16], further justifying more detailed in vitro and in vivo analysis of Tks5 function. Here, SH3PXD2A is linked to brain neoplasm.